ALEC•prnewswire•
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint
Summary
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Alector, Inc. (NASDAQ: ALEC) following the Company's announcement of topline results from its Phase 3 INFRONT-3 trial, evaluating latozinemab in individuals with frontotemporal dementia due to a gene mutation...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 29, 2026 by prnewswire